Supplementary Figure S1 Details from Co-occurring Genomic Alterations Define Major Subsets of &lt;i&gt;KRAS&lt;/i&gt;-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities